New study checks if IBD drug skyrizi seeps into breast milk
NCT ID NCT06346288
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how much of the drug risankizumab (Skyrizi) passes into the breast milk of women with inflammatory bowel disease (IBD). Ten breastfeeding mothers who were already taking the drug provided milk samples over several weeks. The goal is to understand potential exposure to nursing infants and help guide safe breastfeeding recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
risankizumab (Skyrizi)
What this could lead to
If successful, this study could provide data to help doctors and mothers make informed decisions about breastfeeding while on risankizumab.
What could go wrong
This is a small, observational study with only 10 participants. It measures drug levels in milk but does not directly test infant safety or long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shaare Zedek Medical Center /ID# 262738
Jerusalem, Jerusalem, 91031, Israel
-
UTHealth Women's Research Program - Memorial City /ID# 263939
Houston, Texas, 77024, United States
-
University of North Carolina at Chapel Hill /ID# 263316
Chapel Hill, North Carolina, 27514, United States